Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyThe Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
Additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories
Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.